U.S. Markets close in 57 mins
  • S&P 500

    4,686.94
    +95.27 (+2.07%)
     
  • Dow 30

    35,744.72
    +517.69 (+1.47%)
     
  • Nasdaq

    15,679.38
    +454.23 (+2.98%)
     
  • Russell 2000

    2,268.50
    +65.02 (+2.95%)
     
  • Crude Oil

    71.88
    +2.39 (+3.44%)
     
  • Gold

    1,785.40
    +5.90 (+0.33%)
     
  • Silver

    22.54
    +0.28 (+1.24%)
     
  • EUR/USD

    1.1264
    -0.0023 (-0.2027%)
     
  • 10-Yr Bond

    1.4790
    +0.0450 (+3.14%)
     
  • Vix

    21.97
    -5.21 (-19.17%)
     
  • GBP/USD

    1.3238
    -0.0023 (-0.1721%)
     
  • USD/JPY

    113.6060
    +0.1160 (+0.1022%)
     
  • BTC-USD

    50,926.64
    +1,722.17 (+3.50%)
     
  • CMC Crypto 200

    1,314.20
    -7.08 (-0.54%)
     
  • FTSE 100

    7,339.90
    +107.62 (+1.49%)
     
  • Nikkei 225

    28,455.60
    +528.23 (+1.89%)
     

SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - October 11, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021.

If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20315&wire=5

Allegations against SAVA include that the Company made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.

If you suffered a loss in Cassava you have until October 26, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99272